OBJECTIVES: Mucosal damage is an important and debilitating side effect when treating head and neck cancer patients with (chemo-)radiation. The aim of this randomized clinical trial was to investigate whether the addition of a neutral, supersaturated, calcium phosphate (CP) mouth rinse benefits the severity and duration of acute mucositis in head and neck cancer patients treated with (chemo)radiation. MATERIALS AND METHODS: A total of 60 patients with malignant neoplasms of the head and neck receiving (chemo)radiation were included in this study. Fifty-eight patients were randomized into two treatment arms: a control group receiving standard of care (n = 31) and a study group receiving standard of care + daily CP mouth rinses (n = 27) starting on the first day of (chemo-)radiation. Oral mucositis and dysphagia were assessed twice a week using the National Cancer Institute common toxicity criteria scale version 3, oral pain was scored with a visual analogue scale. RESULTS: No significant difference in grade III mucositis (59 vs. 71 %; p = 0.25) and dysphagia (33 vs. 42 %, p = 0.39) was observed between the study group compared to the control group. Also no significant difference in time until development of peak mucositis (28.6 vs. 28.7 days; p = 0.48), duration of peak mucositis (22.7 vs. 24.6 days; p = 0.31), recuperation of peak dysphagia (20.5 vs 24.2 days; p = 0.13) and occurrence of severe pain (56 vs. 52 %, p = 0.5). CONCLUSION: In this randomized study, the addition of CP mouth rinse to standard of care did not improve the frequency, duration or severity of the most common acute toxicities during and early after (chemo)radiation. There is currently no evidence supporting its standard use in daily practice.
RCT Entities:
OBJECTIVES:Mucosal damage is an important and debilitating side effect when treating head and neck cancerpatients with (chemo-)radiation. The aim of this randomized clinical trial was to investigate whether the addition of a neutral, supersaturated, calcium phosphate (CP) mouth rinse benefits the severity and duration of acute mucositis in head and neck cancerpatients treated with (chemo)radiation. MATERIALS AND METHODS: A total of 60 patients with malignant neoplasms of the head and neck receiving (chemo)radiation were included in this study. Fifty-eight patients were randomized into two treatment arms: a control group receiving standard of care (n = 31) and a study group receiving standard of care + daily CP mouth rinses (n = 27) starting on the first day of (chemo-)radiation. Oral mucositis and dysphagia were assessed twice a week using the National Cancer Institute common toxicity criteria scale version 3, oral pain was scored with a visual analogue scale. RESULTS: No significant difference in grade III mucositis (59 vs. 71 %; p = 0.25) and dysphagia (33 vs. 42 %, p = 0.39) was observed between the study group compared to the control group. Also no significant difference in time until development of peak mucositis (28.6 vs. 28.7 days; p = 0.48), duration of peak mucositis (22.7 vs. 24.6 days; p = 0.31), recuperation of peak dysphagia (20.5 vs 24.2 days; p = 0.13) and occurrence of severe pain (56 vs. 52 %, p = 0.5). CONCLUSION: In this randomized study, the addition of CP mouth rinse to standard of care did not improve the frequency, duration or severity of the most common acute toxicities during and early after (chemo)radiation. There is currently no evidence supporting its standard use in daily practice.
Authors: Jan E Clarkson; Helen V Worthington; Susan Furness; Martin McCabe; Tasneem Khalid; Stefan Meyer Journal: Cochrane Database Syst Rev Date: 2010-08-04
Authors: L Vagliano; C Feraut; G Gobetto; A Trunfio; A Errico; V Campani; G Costazza; A Mega; V Matozzo; M Berni; F Alberani; M M Banfi; L Martinelli; S Munaron; L Orlando; L Lubiato; S Leanza; R Guerrato; A Rossetti; M Messina; L Barzetti; G Satta; V Dimonte Journal: Bone Marrow Transplant Date: 2010-09-06 Impact factor: 5.483
Authors: Giuseppe Sanguineti; Maria Pia Sormani; Shanthi Marur; G Brandon Gunn; Nikhil Rao; Marco Cianchetti; Francesco Ricchetti; Todd McNutt; Binbin Wu; Arlene Forastiere Journal: Int J Radiat Oncol Biol Phys Date: 2011-11-19 Impact factor: 7.038
Authors: Dorothy M Keefe; Mark M Schubert; Linda S Elting; Stephen T Sonis; Joel B Epstein; Judith E Raber-Durlacher; Cesar A Migliorati; Deborah B McGuire; Ronald D Hutchins; Douglas E Peterson Journal: Cancer Date: 2007-03-01 Impact factor: 6.860
Authors: Stephen T Sonis; Linda S Elting; Dorothy Keefe; Douglas E Peterson; Mark Schubert; Martin Hauer-Jensen; B Nebiyou Bekele; Judith Raber-Durlacher; J Peter Donnelly; Edward B Rubenstein Journal: Cancer Date: 2004-05-01 Impact factor: 6.860
Authors: Martee L Hensley; Karen L Hagerty; Tarun Kewalramani; Daniel M Green; Neal J Meropol; Todd H Wasserman; Gary I Cohen; Bahman Emami; William J Gradishar; R Brian Mitchell; J Tate Thigpen; Andy Trotti; Daniel von Hoff; Lynn M Schuchter Journal: J Clin Oncol Date: 2008-11-17 Impact factor: 44.544
Authors: Kranti A Mapuskar; Carryn M Anderson; Douglas R Spitz; Ines Batinic-Haberle; Bryan G Allen; Rebecca E Oberley-Deegan Journal: Semin Radiat Oncol Date: 2019-01 Impact factor: 5.934
Authors: Carryn M Anderson; Stephen T Sonis; Christopher M Lee; Douglas Adkins; Bryan G Allen; Wenqing Sun; Sanjiv S Agarwala; Madhavi L Venigalla; Yuhchyau Chen; Weining Zhen; Diane R Mould; Jon T Holmlund; Jeffrey M Brill; John M Buatti Journal: Int J Radiat Oncol Biol Phys Date: 2017-10-16 Impact factor: 7.038
Authors: Kee H Wong; Aleksandra Kuciejewska; Mansour T A Sharabiani; Brian Ng-Cheng-Hin; Sonja Hoy; Tara Hurley; Joanna Rydon; Lorna Grove; Ana Santos; Motoko Ryugenji; Shreerang A Bhide; Chris M Nutting; Kevin J Harrington; Kate L Newbold Journal: Radiother Oncol Date: 2016-07-05 Impact factor: 6.280
Authors: Carryn M Anderson; Christopher M Lee; Deborah P Saunders; Amarinthia Curtis; Neal Dunlap; Chaitali Nangia; Arielle S Lee; Sharon M Gordon; Philip Kovoor; Roberto Arevalo-Araujo; Voichita Bar-Ad; Abhinand Peddada; Kyle Colvett; Douglas Miller; Anshu K Jain; James Wheeler; Dukagjin Blakaj; Marcelo Bonomi; Sanjiv S Agarwala; Madhur Garg; Francis Worden; Jon Holmlund; Jeffrey M Brill; Matt Downs; Stephen T Sonis; Sanford Katz; John M Buatti Journal: J Clin Oncol Date: 2019-10-16 Impact factor: 44.544